Download PDF
Z Gastroenterol 2004; 42(3): 233-242
DOI: 10.1055/s-2004-812729
Kasuistik
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Gastrointestinale Stromatumoren (GIST): variable klinische Manifestationen vom Zufallsbefund bis zur akuten gastrointestinalen Blutung

Gastrointestinal Stromal Tumors: a Broad Clinical Spectrum from Incidental ­Discovery to Acute Gastrointestinal BleedingE. Siewert1 , L. Tietze2 , C. Maintz3 , A. Geier1 , C. G. Dietrich1 , S. Matern1 , C. Gartung1
  • 1Medizinische Klinik III, Universitätsklinikum Aachen, Aachen
  • 2Institut für Pathologie, Universitätsklinikum Aachen, Aachen
  • 3Hämatologisch-onkologische Praxis, Würselen
Further Information

Publication History

Manuskript eingetroffen: 4.4.2003

Manuskript akzeptiert: 27.11.2003

Publication Date:
15 March 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Drei Fallbeispiele verdeutlichen das breite klinische Spektrum gastrointestinaler Stromatumoren (GIST), der häufigsten Untergruppe gastrointestinaler mesenchymaler Tumoren (GIMT), mit daraus resultierenden Folgen für Therapie und Prognose. Die erste Kasuistik beschreibt einen 82-jährigen Patienten mit einer hämodynamisch wirksamen oberen gastrointestinalen Blutung, deren Ursache ein GIST des Magens war. Gastrointestinale Blutungen sind neben abdominellen Schmerzen und tastbaren oder sonographisch nachweisbaren abdominellen Raumforderungen die typischen klinisch apparenten Manifestationen dieser Tumoren. In der zweiten Kasuistik wird ein GIST bei einer 44-jährigen Patientin als Zufallsbefund erhoben, beispielhaft für den andererseits oft asymptomatischen Verlauf. Übersichtsartig werden die mittlerweile durch immunhistochemische Methoden gut zu differenzierenden Tumorgruppen vorgestellt, die man heute unter dem Begriff der gastrointestinalen mesenchymalen Tumoren (GIMT) subsumiert. Ausgehend vom dritten Fallbeispiel eines 40-jährigen GIST-Patienten mit postoperativem Rezidiv und sekundärer Resistenz nach einjähriger überaus erfolgreicher Therapie mit Imatinib (Gleevec®), einem Antagonisten der pathogenetisch relevanten Rezeptortyrosinkinase c-KIT, werden prognostisch wichtige Faktoren gastrointestinaler Stromatumoren (GIST) diskutiert und Möglichkeiten und Grenzen dieser ersten effektiven, seit wenigen Jahren verfügbaren medikamentösen Therapie fortgeschrittener GIST dargestellt.

Abstract

Three cases of gastrointestinal stromal tumors (GIST) are reported as typical examples of the broad clinical spectrum in which these rare tumors can be detected. The first case describes an 82-year-old patient with a hemorrhagic shock due to upper gastrointestinal bleeding from a GIST of the stomach. GIST most frequently present with either gastrointestinal bleeding, abdominal pain or a detectable mass on physical examination or by ultrasound imaging. Clinically asymptomatic tumor growth also occurs as demonstrated by the second case of a 44-year-old ­woman with an incidental finding of GIST during surgery of the esophagus. The cases are used to discuss the consequences for therapy and prognosis resulting from the heterogeneity of this tumor entity; the relevant immunohistochemical markers used to distinguish between various tumor subtypes of gastrointestinal mesenchymal tumors (GIMT) are listed. Since gastrointestinal stromal tumors (GIST) represent the most common subgroup of GIMT, we focus on the clinicopathological prognostic factors of GIST. The third case of a 40-year-old patient with a malignant GIST recurrence after surgery and exhibiting secondary resistance after one year of successful therapy with the receptor tyrosine kinase inhibitor imatinib (Gleevec®), antagonizing pathogenetically relevant constitutive c-KIT activation, illustrates the potential and limitations of the only effective drug treatment for advanced GIST.

Schlüsselwörter

Gastrointestinaler mesenchymaler Tumor (GIMT) - gastrointestinaler Stromatumor (GIST) - Schwannom - Leiomyom - gastrointestinale Blutung - STI-571/Imatinib

Key words

Gastrointestinal mesenchymal tumor (GIMT) - gastrointestinal stromal tumor (GIST) - schwannoma - leiomyoma - gastrointestinal bleeding - STI-571/imatinib

Literatur

  • 1 Mazur M T, Clark H B. Gastric stromal tumor: Reappraisal of histogenesis.  Am J Surg Pathol. 1983;  7 507-519
    CrossrefPubMedGoogle Scholar
  • 2 Miettinen M, Lasota J. Gastointestinal stromal tumors - definition, ­clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.  Virchows Arch. 2001;  438 1-12
    CrossrefPubMedGoogle Scholar
  • 3 Fletcher C DM, Berman J J, Corless C. et al . Diagnosis of gastrointestinal stromal tumors: a consensus approach.  Hum Pathol. 2002;  33 459-465
    Google Scholar
  • 4 Eyden B, Chorneyko K A, Shanks J H. et al . Contribution of electron microscopy to understanding cellular differentiation in mesenchymal tumors of the gastrointestinal tract: a study of 82 tumors.  Ultrastruct Pathol. 2002;  26 269-285
    PubMedGoogle Scholar
  • 5 Lee J R, Joshi V, Griffin J r JW. et al . Gastrointestinal autonomic nerve ­tumor - immunohistochemical and meolecular identity with gastrointestinal stromal tumor.  Am J Surg Pathol. 2001;  25 979-987
    CrossrefPubMedGoogle Scholar
  • 6 Hirota S. Gastrointestinal stromal tumors: their origin and cause.  Int J Clin Oncol. 2001;  6 1-5
    PubMedGoogle Scholar
  • 7 Sarlomo-Rikala M, Miettinen M. Gastric schwannoma - a clinicopathological analysis of six cases.  Histopathology. 1995;  27 355-360
    PubMedGoogle Scholar
  • 8 Kwon M S, Lee S S, Ahn G H. Schwannomas of the gastrointestinal tract: clinicopathological features of 12 cases including a case of esophageal tumor compared with those of gastrointestinal stromal tumors and leiomyomas of the gastrointestinal tract.  Pathol Res Pract. 2002;  198 605-613
    PubMedGoogle Scholar
  • 9 Reichardt P, Pink D, Hohenberger P. Paradigmenwechsel in der Therapie gastrointestinaler Strumatumoren.  Onkologe. 2002;  8 378-383
    CrossrefPubMedGoogle Scholar
  • 10 Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors.  Science. 1998;  279 577-580
    CrossrefPubMedGoogle Scholar
  • 11 van Oosterom A T, Judson I, Verweij J. et al . Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study.  The Lancet. 2001;  358 1421-1423
    CrossrefPubMedGoogle Scholar
  • 12 Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC soft tissue and bone sarcoma group.  Eur J Cancer. 2002;  38, Suppl. 5 S83-S87
    PubMedGoogle Scholar
  • 13 DeMatteo R P, Heinrich M C, El-Rifai W M. et al . Clinical management of gastrointestinal stromal tumors: before and after STI-571.  Hum Pathol. 2002;  33 466-477
    CrossrefPubMedGoogle Scholar
  • 14 Demetri G D, von Mehren M, Blanke C D. et al . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.  N Engl J Med. 2002;  347 472-480
    CrossrefPubMedGoogle Scholar
  • 15 Joensuu H, Robert P J, Sarloma-Rikala M. et al . Effect of the tysrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.  N Engl J Med. 2001;  344 1052-1056
    CrossrefPubMedGoogle Scholar
  • 16 Soft Tissue Sarcomas. DeVita VT, Hellman S, Rosenberg SA Cancer, principles and practice of oncology Philadelphia; Lippincott 1993
    Google Scholar
  • 17 Chou F F, Eng H L, Sheen-Chen S M. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors.  Surgery. 1996;  119 117
    PubMedGoogle Scholar
  • 18 Pidhorecky M D, Cheney R T, Kraybill W G. et al . Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.  Ann Surg Oncol. 2000;  7 705-712
    CrossrefPubMedGoogle Scholar
  • 19 Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract.  Histol Histopathol. 2000;  15 1293-1301
    PubMedGoogle Scholar
  • 20 Sarlomo-Rikala M, Tsujimura T, Lendahl U. et al . Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas.  APMIS. 2002;  110 499-507
    CrossrefPubMedGoogle Scholar
  • 21 Miettinen M, Sobin L H, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).  Mod Pathol. 2000;  13 1134-1142
    CrossrefPubMedGoogle Scholar
  • 22 Hornick J L, Fletcher C DM. Immunohistochemical staining for KIT (CD117) in soft tissue sacomas is very limited in distribution.  Am J Clin Pathol. 2002;  117 188-193
    CrossrefPubMedGoogle Scholar
  • 23 Miettinen M, Salomo-Rikala M, Sobin L H. et al . Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas.  Am J Surg Pathol. 2000;  24 211-222
    CrossrefPubMedGoogle Scholar
  • 24 Miettinen M, Salomo-Rikala M, Sobin L H. Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors - a clinicopathologic and immunohistochemical study of eighty-eight cases.  Mod Pathol. 2001;  14 950-956
    CrossrefPubMedGoogle Scholar
  • 25 Plaat B E, Hollema H, Molenaar W M. et al . Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.  J Clin Oncol. 2000;  18 3211-3220
    PubMedGoogle Scholar
  • 26 Miettinen M, El-Rifai W, Sobin. et al . Evaluation of malignancy and prognosis of gastrointestinal stromal tumors.  Hum Pathol. 2002;  33 478-483
    CrossrefPubMedGoogle Scholar
  • 27 Mechtersheimer G, Lehnert T, Penzel R. et al . Gastrointestinale Stromatumoren - eine morphologisch und molekular eigenständige Tumorentität mit neuer therapeutischer Perspektive.  Pathologe. 2003;  24 182-191
    PubMedGoogle Scholar
  • 28 Heinrich M C, Rubin B P, Longley B J. et al . Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.  Hum Pathol. 2002;  33 484-495
    CrossrefPubMedGoogle Scholar
  • 29 Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.  Eur J Cancer. 2002;  38, Suppl. 5 S39-S51
    Google Scholar
  • 30 Paner G P, Silberman S, Hartman G. et al . Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors.  Anticancer Res. 2003;  23 2253-2260
    PubMedGoogle Scholar
  • 31 Heinrich M C, Corless C L, Blanke C D. et al . KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors.  Proc Am Soc Clin Oncol. 2002;  21 2 a (abstract)
    PubMedGoogle Scholar
  • 32 Joensuu H, Fletcher C, Dimitrijevic S. et al . Management of malignant gastrointestinal stromal tumors.  Lancet Oncol. 2002;  3 655-664
    CrossrefPubMedGoogle Scholar
  • 33 Roberts P J, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease.  Euro J Cancer. 2002;  38 (Suppl. 5) S37-S38
    PubMedGoogle Scholar
  • 34 DeMatteo R P, Lewis J J, Leung D. et al . Two hundred gastrointestinal stromal tumors - recurrence patterns and prognostic factors for survival.  Ann Surg. 2000;  231 51-58
    CrossrefPubMedGoogle Scholar
  • 35 DeMatteo R P. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-KIT), and a molecular inhibitor (STI571).  Ann Surg Oncol. 2002;  9 831-839
    PubMedGoogle Scholar
  • 36 Brümming P, Andersson J, Meis-Kindblom J M. et al . Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.  Br J Cancer. 2003;  89 460-464
    CrossrefPubMedGoogle Scholar
  • 37 von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.  Leukemia. 2003;  17 829-838
    CrossrefPubMedGoogle Scholar
  • 38 Paterson S C, Smith K D, Holyoake T L. et al . Is there a cloud in the silver lining for imatinib?.  Br J Cancer. 2003;  88 983-987
    CrossrefPubMedGoogle Scholar
  • 39 Thambi P, Sausville E A. STI571 (imatinib mesylate): the tale of a targeted therapy.  Anti-Cancer Drugs. 2002;  13 111-114
    CrossrefPubMedGoogle Scholar

Prof. Dr. Carsten Gartung

Medizinische Klinik III, Universitätsklinikum der RWTH Aachen

Pauwelsstr. 30

52074 Aachen

Email: carsten.gartung@post.rwth.aachen.de